Alimera Sciences, Inc. (NASDAQ:ALIM) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, August 1st. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. The company had revenue of $6.62 million for the quarter, compared to the consensus estimate of $8.80 million. During the same period in the previous year, the business earned ($0.22) EPS. The business’s quarterly revenue was up 14.1% compared to the same quarter last year. On average, analysts expect Alimera Sciences to post $-0.25 EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

Shares of Alimera Sciences, Inc. (NASDAQ ALIM) opened at 1.46 on Tuesday. The stock’s market capitalization is $94.76 million. Alimera Sciences, Inc. has a 52-week low of $1.01 and a 52-week high of $2.40. The firm’s 50-day moving average is $1.40 and its 200 day moving average is $1.37.

ILLEGAL ACTIVITY NOTICE: “Alimera Sciences, Inc. (ALIM) to Release Quarterly Earnings on Tuesday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/07/25/alimera-sciences-inc-alim-to-release-quarterly-earnings-on-tuesday.html.

ALIM has been the subject of several research reports. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 30th. Rodman & Renshaw started coverage on shares of Alimera Sciences in a research note on Thursday, April 27th. They set a “buy” rating and a $4.00 price objective for the company. HC Wainwright set a $5.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Cowen and Company restated a “buy” rating and set a $3.00 price target on shares of Alimera Sciences in a research note on Tuesday, July 11th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.38.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Earnings History for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.